2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Somatostatin Receptor

Somatostatin Receptor

SSTRs; SSTR

Somatostatin Receptor

Related Products

PDF 0.61 MB

Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family. Somatostatin receptors are expressed in a variety of human tumors, including most tumors of neuroendocrine origin, breast tumors, certain brain tumors, renal cell tumors, lymphomas, and prostate cancer. Somatostatin triggers cytostatic and cytotoxic effects and has a general inhibitory effect on secretion mediated through its interaction with somatostatin receptors.

The SSTRs 1-4 display weak selectivity for somatostatin-14 binding, whereas SSTR5 is somatostatin-28-selective. Based on structural similarity and reactivity for octapeptide and hexapeptide somatostatin receptor analogs, SSTRs 2, 3 and SSTR5 belong to a similar somatostatin receptor subclass; SSTRs 1-4 react poorly with these analogs and belong to a separate subclass. All five somatostatin receptors are functionally coupled to inhibition of adenylyl cyclase via pertussis toxin-sensitive guanosine triphosphate (GTP)-binding proteins. mRNA for SSTRs 1-5 is widely expressed in brain and peripheral organs and displays an overlapping but characteristic pattern that is subtype-selective and tissue- and species-specific. All pituitary cell subsets express SSTR2 and SSTR5, with SSTR5 being more abundant. Individual pituitary cells coexpress multiple somatostatin receptor subtypes.

Somatostatin Receptor Isoform Specific Products:

Somatostatin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4992
    Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11)
    		Agonist
    Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist that can be used in cancer research.
    Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11)
  • HY-P3124
    BIM-23190
    		Agonist
    BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly.
    BIM-23190
  • HY-P0036B
    Octreotide pamoate
    		Agonist
    Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
    Octreotide pamoate
  • HY-110161
    sst2 Receptor agonist-1
    		Agonist
    sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst2) agonist with a Ki value of 0.025 nM and a cAMP IC50 value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect.
    sst2 Receptor agonist-1
  • HY-P1201A
    Cyclosomatostatin TFA
    		Antagonist
    Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.
    Cyclosomatostatin TFA
  • HY-106103
    Seglitide
    		Agonist
    Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes.
    Seglitide
  • HY-105172A
    TT-232 TFA
    		Agonist
    TT-232 TFA (CAP-232 TFA) is an analogue of somatostatin. TT-232 TFA can induce apoptosis of pancreatic tumor cell lines, inhibit tyrosine kinase activity and stimulate tyrosine phosphatase activity in colon tumor cell lines. TT-232 TFA inhibits the proliferation of tumor cells, induces apoptosis of tumor cells and shows strong anti-tumor effects. TT-232 TFA can be used in the development of anti-tumor drugs and the study of apoptosis mechanism.
    TT-232 TFA
  • HY-RS13828
    Sstr3 Rat Pre-designed siRNA Set A
    		Inhibitor

    Sstr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr3 Rat Pre-designed siRNA Set A
    Sstr3 Rat Pre-designed siRNA Set A
  • HY-108499
    NNC 26-9100
    		Agonist
    NNC 26-9100 is a selective somatostatin sst4 receptor full agonist (Ki: 6 nM, EC50: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning.
    NNC 26-9100
  • HY-142699
    SSTR4 agonist 2
    SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107).
    SSTR4 agonist 2
  • HY-P2229
    Ilatreotide
    Ilatreotide (SDZ CO61), glycated somatostatin derivative, is a highly potent glycated analog of somatostatin with improved oral activity. Ilatreotide can suppress the fasting level and postprandial release of several gastrointestinal and pancreatic hormones. Ilatreotide can be used for the research of gastroenteropancreatic tumors.
    Ilatreotide
  • HY-RS13834
    Sstr5 Rat Pre-designed siRNA Set A
    		Inhibitor

    Sstr5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr5 Rat Pre-designed siRNA Set A
    Sstr5 Rat Pre-designed siRNA Set A
  • HY-RS13827
    Sstr3 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Sstr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr3 Mouse Pre-designed siRNA Set A
    Sstr3 Mouse Pre-designed siRNA Set A
  • HY-120287
    L-054522
    		Agonist
    L-054522 is an agonist for somatostatin receptor subtype 2 with Kd of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC50=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC50=0.05 nM and 12 nM).
    L-054522
  • HY-P3952
    (D-Trp8,D-Cys14)-Somatostatin-14
    		Control
    (D-Trp8,D-Cys14)-Somatostatin-14 is a Somatostatin synthetic analogue. (D-Trp8,D-Cys14)-Somatostatin-14 can be used for the research of metabolic related diseases.
    (D-Trp8,D-Cys14)-Somatostatin-14
  • HY-P2112
    DOTA-NOC
    DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging. DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-NOC
  • HY-163317
    MMC(TMZ)-TOC
    MMC(TMZ)-TOC has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC can be used for the research of cancer.
    MMC(TMZ)-TOC
  • HY-RS13826
    SSTR3 Human Pre-designed siRNA Set A
    		Inhibitor

    SSTR3 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SSTR3 Human Pre-designed siRNA Set A
    SSTR3 Human Pre-designed siRNA Set A
  • HY-RS13831
    Sstr4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Sstr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr4 Rat Pre-designed siRNA Set A
    Sstr4 Rat Pre-designed siRNA Set A
  • HY-142929
    MAT2A-IN-2
    		Inhibitor
    MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172).
    MAT2A-IN-2
Cat. No. Product Name / Synonyms Application Reactivity
Somatostatin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.